Sugi Predict

Sugi Predict / Compounds / SCHEMBL1472239

SCHEMBL1472239

SCHEMBL1472239

O=[N+]([O-])c1ccc(Oc2c(Cl)cc(S(=O)(=O)NCCc3ccc(O)cc3)cc2Cl)c(Cl)c1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ THRA P10827 3/20 0.54
▸ CA1 P00915 2/20 0.48
▸ CA2 P00918 2/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ POLB P06746 1/20 0.48
▸ MEN1 O00255 4/20 0.45
▸ KMT2A Q03164 4/20 0.45
▸ PKM P14618 3/20 0.45
▸ MAPT P10636 2/20 0.45
▸ HTT P42858 1/20 0.45
▸ LMNA P02545 2/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ GAA P10253 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ PDE7A Q13946 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1471923 0.89 ALDH1A1 (0.54) THRACA1CA2CYP2C9POLB
SCHEMBL1472015 0.82 THRA (0.52) THRACA1CA2CYP2C9POLB
SCHEMBL1473974 0.82 THRA (0.52) THRACA1CA2CYP2C9MEN1
SCHEMBL1473683 0.80 THRA (0.51) THRACA1CA2CYP2C9POLB
SCHEMBL13485840 0.80 THRA (0.59) THRACA1CA2CYP2C9MEN1
SCHEMBL6369182 0.79 THRA (0.55) THRACA2CYP2C9MEN1KMT2A
SCHEMBL1472155 0.78 RAB9A (0.60) THRACA1CA2CYP2C9HTT
SCHEMBL1472225 0.78 THRA (0.52) THRACYP2C9MEN1KMT2APKM
SCHEMBL1471301 0.78 CYP2C9 (0.56) THRACYP2C9MEN1KMT2APKM
SCHEMBL1471655 0.78 THRA (0.66) THRACYP2C9MEN1KMT2APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915293-B2 Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases RIGEL PHARMACEUTICALS, INC. (US) 2011-03-29 — — US disclosed
US-7915293-B2 Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases RIGEL PHARMACEUTICALS, INC. (US) 2011-03-29 — — US disclosed
US-7915293-B2 Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases RIGEL PHARMACEUTICALS, INC. (US) 2011-03-29 — — US disclosed
WO-2005007621-A2 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2005-01-27 — — WO disclosed
US-20050009871-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. 2005-01-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009871-A1 Ubiquitin ligase inhibitors NEDD4, STUB1, UBE3A THRA 4803/4885CA1 4059/4885CA2 4143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.